Endovascular repair for retrograde type A intramural hematoma with focal intimal disruption in descending aorta.

BACKGROUND: This study aims to report the experience of a single center using thoracic endovascular aortic repair (TEVAR) to treat retrograde type A intramural hematoma (IMH) with focal intimal disruption (FID) in descending aorta.
METHODS: A total of 24 consecutive patients with retrograde type A IMH and complicated with FID in descending aorta underwent TEVAR in our center from 2015 to 2020. Their clinical data, imaging manifestation and follow-up results were retrospectively reviewed and analyzed.
RESULTS: The median age of patients was 57.9 years (range, 42-80 years) and 18 were men (75%). As the preoperative CT angiography showed, the 24 patients developed IMH complicated with different kinds of FIDs in descending aorta [5 had intramural blood pool (IBP), 15 had ulcer-like projection (ULP), 2 had penetrating atherosclerotic ulcer (PAU), and 5 had localized dissection]. Successful deployment of aortic stent graft was achieved in all patients. There was no endoleak, stent graft migration, spinal cord ischemia, stroke, or 30-day mortality observed after TEVAR. The median duration of follow-up was 30.0 months (range, 3-60 months). As the last follow-up CT angiography showed, most of the patients (23 in 24, 96%) had favorable aortic remodeling. The maximum hematoma thicknesses and maximum diameters of both ascending and descending aorta were significantly decreased. During follow-up, 1 patient developed retrograde type A aortic dissection (RAAD) and underwent open surgery 3 months after TEVAR. 1 patient died of lung cancer 2 years later. There was no aorta-related death observed.
CONCLUSIONS: TEVAR provides a safe and effective treatment strategy for selected patients with retrograde type A IMH, and FID developed in descending aorta could be the possible treatment target. However, RAAD remains one of the most serious postoperative complications of concern. 2021 Journal of Thoracic Disease. All rights reserved.

Introduction

Aortic intramural hematoma (IMH) is an emergency and life-threatening medical condition belonging to the spectrum of acute aortic syndrome (1). Unlike the classic aortic dissection, IMH is characterized by the presence of a hematoma within the aortic wall and manifests as crescent or circular aortic wall thickening. Although IMH doesn’t present as overt false lumen, focal intimal disruption (FID) could be detected in 70% of IMH with high resolution computed tomography (2). The FIDs include ulcer-like projection (ULP), penetrating atherosclerotic ulcer (PAU), intramural blood pool (IBP) and localized dissection, which are regarded as risk factors for the deterioration of IMH (3-5).

The optimal treatment for IMH remains controversial, especially for those involving ascending aorta. The evolution of IMH could be quite elusive, as it could be completely absorbed, progress to aortic dissection or even cause aortic rupture. Retrograde type A IMH is a special subtype of IMH that develops in a retrograde way with primary intimal disruption located in descending aorta. Open surgery was thought to be the most effective treatment for type A IMH, though initial medical treatment showed good outcomes in selected patients (6,7). However, open surgery is usually associated with high mortality and morbidity, and maybe not suitable for patients with poor status. Thoracic endovascular aortic repair (TEVAR) is a less invasive alternative and its value for descending thoracic aortic diseases has been well confirmed (8). And recently several studies have reported the application of TEVAR in retrograde type A IMH or aortic dissection or IMH to exclude the intimal tear in descending aorta (9-11). TEVAR could be a possible treatment strategy for patients with retrograde type A IMH, but its safety and efficacy are not fully elucidated.

This study is to describe the experience of a single center using TEVAR to treat retrograde type A IMH with FID in descending aorta in selected patients. We present the following article in accordance with the STROBE reporting checklist (available at https://dx.doi.org/10.21037/jtd-21-574).

Methods

Study design and patient enrollment

This retrospective study was performed with approval of the Institutional Ethics Board of the Second Xiangya Hospital of Central South University (NO. 2020S069) and informed consent was obtained from every patient. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). From January 1st 2015 to December 31st 2020, a total of 24 consecutive patients with retrograde type A IMH and complicated with FID in descending aorta underwent TEVAR in our center. Their medical records were retrospectively reviewed and analyzed. Patients who met the following criteria were considered to be candidates for TEVAR: (I) there was no intimal disruption in ascending aorta and proximal aortic arch; (II) the maximum hematoma thickness of ascending aorta was no more than 15 mm, and maximum diameter of ascending aorta was no more than 55 mm; (III) there was no signs of cardiac tamponade, severe aortic regurgitation, or involvement of the coronary artery by hematoma. Before the operation, a multidisciplinary board was consulted to determine the operation strategy, which included vascular and cardiovascular surgeons, an anesthesiologist and a radiologist. Patient enrollment of the study was presented in .

Figure 1

Flow chart for patient enrollment.

IMH was diagnosed as the presence of a circular or crescent-shaped thickening of at least 5 mm of the aortic wall with the absence of visible intimal flap in CT angiography. The FID types including ULP, PAU, IBP and localized dissection were defined according to previous publications (3-5). All the 4 types of FIDs could be well detected by CT angiography: ULP protrudes from the lumen to thrombosed media, PAU is the ulceration through an atherosclerotic plaque, IBP has no obvious communication with the lumen, while localized dissection has the manifestation of “true and false lumen”. The measurement of maximum hematoma thickness and maximum diameter of both ascending and descending aorta were performed by three personnel and the average value was chosen in the study.

Operative details and device selection

All patients received a CT angiography at admission, and medical treatment with antihypertensive drugs and beta-blockers were administrated immediately. Those with stable conditions would take a repeated CT angiography about one week later. TEVAR is indicated if the patient presented recurrent chest pain, uncontrollable hypertension, significant progression of IMH or FID. Among the 24 patients, 21 underwent standard TEVAR as previously reported (9,12), while 1 underwent TEVAR with chimney technique and 2 underwent TEVAR with physician modified fenestration to preserve left subclavian artery as we previously reported (13). As the treatment goal is to cover FID in descending aorta, there should be at least 2 cm of proximal and distal sealing. The procedures were performed in a hybrid unit with fluoroscopic guidance, and general anesthesia with tracheal intubation was applied in all patients.

The selected diameter size of the stent graft was 10–15% greater than the diameter of the aorta at the proximal sealing zone measured in aortic angiography. Three types of commercially available stent grafts were implanted in the 24 patients. The Medtronic Valiant thoracic endovascular stent graft (Medtronic, Inc., Minneapolis, MN, USA) was used in 6 patients. The MicroPort Hercules stent graft (MicroPort Medical Shanghai Co, Ltd., Shanghai, China) was used in 2 patients. The Lifetech Ankura stent graft (Lifetech Scientific Co, Ltd., Shenzhen, China) was used in the rest 16 patients.

Follow-up

All of the patients were scheduled with follow-up physical examination and CT angiography 2 weeks, 3 months, 6 months, and 12 months after TEVAR, and annually thereafter to evaluate stent-graft position, endoleaks, and changes of aortic pathologies. Survival was assessed by outpatient clinic visit or telephone interview.

Statistical analysis

Descriptive statistics were used to describe patient data and outcomes in this cohort. The values were expressed as mean ± standard deviation or as medians (ranges). Normality was assessed using the Shapiro-Wilk test. The maximal diameters of aorta and maximum hematoma thickness before and after TEVAR were compared with Student paired t-test. P<0.05 was considered statistically significant. Statistical analysis was conducted using GraphPad 7.0 (GraphPad Software, Inc., San Diego, CA, USA).

Results

Baseline characteristics and preoperative imaging manifestation

The median age of the 24 patients was 57.9 years (range, 42–80 years) and 18 were men (75%). Their baseline characteristics were presented in . There were 6 patients complicated with pericardial effusion and 13 patients with pleural effusion, but drainage of the effusions was not required.

Table 1

Baseline characteristics of the 24 patients

Variables	Number or mean	Range or %
Age, y	57.9±7.1	42–80
Male	18	75%
Comorbidities
Hypertension	23	96%
Coronary heart disease	3	13%
Diabetes	2	8%
Renal dysfunction	2	8%
COPD	2	8%
History of stroke	1	4%
Smoking	12	50%
Pleural effusion	13	54%
Pericardial effusion	6	25%

COPD, chronic obstructive pulmonary diseases.

The preoperative imaging manifestations were summarized in . The 24 patients developed different types of FIDs (5 had IBP, 15 had ULP, 2 had PAU, and 5 had localized dissection) in descending aorta. Among them, 1 had both ULP and IBP, and 2 had ULP that progressed to localized dissection. Twenty patients had crescent shape of hematoma, and 4 patients presented with circular shape. Sixteen patients had more than one preoperative CT angiography. Four patients had newly developed FIDs (1 with ULP, 1 with ULP and IBP, 2 with localized dissections) in late repeated CT angiography, while presented without FID in the initial CT angiography on admission. Nine patients showed progressed FIDs, among whom 4 had significant enlarged ULP in the second CT angiography, and the ULP in 2 progressed to localized dissection after 7 days’ medical treatment (), 1 had enlarged PAU, and 2 developed progressive IBP (),

Table 2

Preoperative imaging manifestations

Variables	Number or mean	Range or %
Shape of hematoma
Crescent	20	83
Circular	4	17
Types of FIDs
IBP	5	21
ULP	15	63
PAU	2	8
Localized dissection	5	21
Patients with repeated preoperative CTA	16	67
Patients with newly developed FIDs	4	17
Patients with progressed FIDs	9	38
CT Measurement
MHT of ascending aorta	8.3±1.8	5.0–12.3
MD of ascending aorta	48.5±2.7	40.9–55.0
MHT of descending aorta	11.7±2.8	6.2–18.5
MD of descending aorta	40.9±3.6	34.2–54.0

FID, focal intimal disruption; IBP, intramural blood pool; ULP, ulcer-like projection; PAU, penetrating atherosclerotic ulcer; MHT, maximum hematoma thickness; MD, maximum diameter.

Figure 2

TEVAR for retrograde type A IMH with a progressive ULP in descending aorta. CT angiography on admission showed retrograde type A IMH with a ULP in descending aorta (red arrow showed) (A,B). After 1 week’s medical treatment, the CT angiography showed the ULP had progressed to a localized dissection (red arrow showed) (C,D). Then the patient underwent TEVAR (E), and CT angiography demonstrated good aortic remodeling 3 months later (F). TEVAR, thoracic endovascular aortic repair; IMH, intramural hematoma; ULP, ulcer-like projection.

Figure 3

TEVAR for retrograde type A IMH with progressive IBPs in descending aorta. CT angiography on admission showed retrograde type A IMH with an IBP in descending aorta (red arrow showed) (A). After 1 week’s medical treatment, CT angiography showed the IBP had significantly progressed (red arrow showed) (B,C). Then TEVAR was performed (D). CT angiography demonstrated good aortic remodeling 3 months later (E,F). TEVAR, thoracic endovascular aortic repair; IMH, intramural hematoma; IBP, intramural blood pool.

Perioperative results

Successful deployment of aortic stent graft was achieved in all patients. The perioperative and follow-up results were shown in . Among the 24 patients, 12 underwent TEVAR in acute phase (1–14 days), 7 underwent TEVAR in sub-acute phase (15–30 days), and the remaining 5 patients underwent TEVAR in chronic phase (>30 days after symptom onset). One patient underwent TEVAR as long as 11 months since the first admission, as he had recurrent chest pain and CT angiography revealed a newly developed ULP. The mean operative time was 78.5±14.7 min (range, 55–120 min). One patient entered ICU after TEVAR, and the ICU stay was 2 days. Chest radiography and echocardiography showed that the pericardial and pleural effusion decreased after TEVAR and were mostly re-absorbed 7–30 days later.

Table 3

Perioperative and follow-up results

Variables	Number or mean	Range or %
Operation time, minutes	78.5±14.7	55–120
Hospital stay, days	20.4±3.5	13–28
Patients lost follow-up	1	4
Follow-up time, months	30.0±16.9	3–60
Interval from symptom onset to TEVAR
1–14 d	12	50
15–30 d	7	29
>30 d	5	21
30-day mortality	0	0
Type A aortic dissection	1	4
Re-intervention	0	0
Aorta-related mortality	0	0
All-cause mortality	1	4

TEVAR, thoracic endovascular aortic repair.

There was no aortic rupture, neurological defect, access site complication, spinal cord ischemia, endoleak or stent graft migration observed after TEVAR. And there was no 30-day mortality.

Follow-up outcome and aortic remodeling

There were 23 patients kept in follow-up after discharge. One patient was lost to follow-up 3 months after TEVAR. The mean duration of follow-up was 30.0±16.9 months (range, 3–60 months). One patient developed retrograde type A aortic dissection (RAAD) and underwent open surgery 3 months after TEVAR. 1 patient died 2 years after TEVAR due to progression of lung cancer. There was no other adverse events or aorta-related death observed during follow-up.

All the patients had satisfactory aortic remodeling after TEVAR (as showed), except the one who developed RAAD. The last follow-up CT angiography demonstrated the maximum hematoma thicknesses of both ascending and descending aorta were significantly decreased (from 8.3±1.8 to 3.0±1.8 mm, P<0.05, and from 11.7±2.8 to 3.7±2.0 mm, P<0.05). And the maximum diameters of both ascending and descending aorta were also significantly decreased (from 47.5±2.7 to 42.7±3.6 mm, P<0.05, and from 40.9±3.6 to 34.6±3.0 mm, P<0.05) (). Complete resolution of IMH (maximum hematoma thicknesses <3 mm) in the ascending aorta was found in 18 patients (75%), and complete resolution of IMH in the descending aorta occurred in 13 patients (54%).

Figure 4

Aortic remodeling of the patients with retrograde type A IMH after TEVAR. The maximal diameters of ascending aorta (A) and descending aorta (B) in follow-up was significantly decreased compared with that on admission. Maximum hematoma thickness of ascending aorta (C) and descending aorta (D) in follow-up was significantly decreased compared with that on admission. Mean values ± SD are shown in the dots with bars. IMH, intramural hematoma; TEVAR, thoracic endovascular aortic repair.

Discussion

The present study tried to verify the effect and safety of TEVAR in selected patients with retrograde type A IMH and FID in descending aorta. During a period of 6 years, a series of 24 consecutive patients were treated with TEVAR. The early and mid-term outcomes showed low incidence of adverse complications and favorable aortic remodeling after operation. IMH in both ascending aorta and descending aorta were significantly decreased. The ascending aorta seemed to have a higher rate of complete resolution of IMH, possibly due to the fact that IMH in ascending aorta was generally milder than descending aorta.

The management of IMH could be challenging, mostly because of its variable natural history and highly unpredictable behavior. FID has prognostic value for IMH, and may provide guidance for clinical decision-making (5). The patients in our series presented different types of FIDs (IBP in 5, ULP in 15, PAU in 2, LD in 5). Twenty patients had FIDs in the CT angiography at admission, while 4 patients showed late developed FIDs in the secondary CT angiography. And 9 patients showed progressive changes of FIDs (4 with enlarged ULP, 1 with enlarged PAU, 2 with progressive IBP, and 2 with ULP progressed to localized dissection). The FIDs are also the targets for endovascular repair. Covering of FIDs could potentially block blood flow into the aortic wall and help to get better aortic remodeling.

Retrograde type A IMH is a special subtype of IMH with the primary intimal disruption located in descending aorta. The involvement of ascending aorta poses high risk for early progression of the disease, such as type A aortic dissection, tamponade, hemothorax, and even aortic rupture (14,15). Although traditional surgical repair is thought to be an effective therapy for type A IMH, it is reported to be associated with significant morbidity and mortality and is not suitable for patients with poor conditions (16,17).

TEVAR provides a less invasive alternative to open surgery in aortic diseases, and it has been widely used in treating descending aortic lesions (8). And with the progress of technology, such as chimney, fenestrated or branched stent grafts, some arch lesions could also be treated with TEVAR (18-20). Previous studies have demonstrated that the application of regular TEVAR to cover the entry tear in descending aorta is a feasible strategy to treat retrograde type A aortic dissection (9,10,21). A systematic review of endovascular management of retrograde type A IMH or aortic dissection summarized that overall in-hospital mortality was 1.8%, and additional all-cause mortality during follow-up was 5.4%, which indicated that for some certain patients TEVAR might be superior to open surgery (22).

Several groups reported the application of TEVAR in type A IMH, mostly in case reports and small case series (23-26). Grimm et al. reported a series of 8 patients with type A IMH that were successfully treated with regular TEVAR (26). And they raised a novel theory, that the atherosclerotic plaque rupture at the free lateral wall or at the concavity of proximal arch would make IMH tend to affect the entire thoracic aorta, thus could be the targets of TEVAR. Their outcomes were satisfactory, with the hematoma in ascending aorta completely reabsorbed in all the 8 patients. And very recently, Ryoi et al. reported their experience with TEVAR for a series of 18 cases of retrograde type A IMH, among whom 11 presented aortic dissection and 7 presented IMH in descending aorta (11). Another group, Li et al. reported TEVAR for 15 cases with type B aortic dissection associated with retrograde type A IMH (27). Both of the studies showed satisfactory mid-term outcomes with high survival rate and low incidence of adverse events. In the current study, all the 24 patients had IMH with FID in descending aorta and they underwent TEVAR with a low rate of postoperative complications observed. Based on the literature and our experience, TEVAR could be a feasible and effective therapy for retrograde type A IMH with FID in descending aorta.

The optimal timing for TEVAR applied in retrograde type A IMH remains a controversial issue. Typically, urgent surgical repair is recommended for type A IMH or aortic dissection, but studies have demonstrated that initial medical management with timely interventions or the “Watch-and-wait strategy” could achieve good outcomes for retrograde type A IMH or aortic dissection (28-30). As retrograde type A IMH or aortic dissection showed more favorable prognosis than antegrade type A IMH or aortic dissection which had intimal tear in ascending aorta. And the studies of TEVAR in acute type B aortic dissection suggested that appropriate delay of intervention could lower the risk of complications of TEVAR in patients that were stable to wait (31). In the current study, the average time interval between the onset of symptoms and TEVAR was 17.5±8.2 days (range, 7–40 days, with the case of 330 days excluded). The authors advocated appropriate delay of TEVAR in acute retrograde type A IMH and the rationales are as follows: firstly, the aortic wall in acute phase may be fragile to tolerate the deployed stent grafts; secondly, it’s important to make sure there is no newly developed FID or significantly progressed hematoma in ascending aorta, which may otherwise indicate for open surgery.

It is the consensus that ideal proximal seal zone for TEAVR should be in a healthy aorta segment. As some investigators showed, landing on IMH could increase the risk of RAAD after TEVAR (32). For the patients with retrograde type A IMH undergoing TEVAR, development of a new RAAD is one of the most serious complications that should not be ignored. In the current series the rate of RAAD was 4%, and another group also reported the occurrence of RAAD after TEVAR in retrograde type A IMH (24). There are several possible mechanisms. Firstly, as the stent grafts deployed on the aorta segment with IMH, the intima could potentially be injured, especially when there is too much oversizing or a “bird-beak” formed. Secondly, the manipulation of wires and catheters during TEVAR could possibly cause damage to the intima of ascending aorta which already presented with IMH. Thirdly, there may be tiny and unrecognizable intimal tear in the IMH of ascending aorta, which could gradually enlarge and lead to the development of RAAD.

The study has several limitations. Firstly, it is a retrospective and observational study performed in a single center with a relatively small number of patients. Secondly, the study did not include the patients that underwent open surgery or received conservative treatment only. Thirdly, the duration of follow-up is limited, and longer follow-up and observation are needed to confirm the long-term safety.

Conclusions

The current study indicated that TEVAR could be a feasible therapy for retrograde type A IMH with focal intima disruption (FID) in descending aorta. In selected patients, TEVAR seemed to provide an effective and safe strategy with satisfactory early and midterm outcomes and favorable aortic remodeling. And the FID developed in descending aorta could be the possible treatment target for TEVAR. But RAAD remains one of the most serious postoperative complications of concern. And further studies are still warranted in future to testify the long-term durability and safety, as well as to optimize the intervention.

The article’s supplementary files as